Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Rein Therapeutics closed a $57.5 million underwritten public offering of 57.5 million shares at $1.00 per share, including the full exercise of the over-allotment option. The company intends to use the net proceeds to fully fund the Phase 2 RENEW trial of its lead asset LTI-03 in idiopathic pulmonary fibrosis and support operations into the first quarter of 2028.
Key figures
- Deal Value Usd
- 57500000
- Offering Price
- 1
- Shares Offered
- 57500000
- Cash runway
- Q1 2028
- Over allotment shares
- 7500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.